Literature DB >> 19797340

French general practitioners vary in their attitudes toward treating terminally ill patients.

Céline Mas1, Marie-Claire Albaret, Paul C Sorum, Etienne Mullet.   

Abstract

The purpose of this study is to analyze French general practitioners' attitudes toward prescribing opiate painkillers for dying patients and compare them with their attitudes toward making frequent home visits. One hundred and fifteen general practitioners indicated the acceptability of prescribing opiates in 48 scenarios of terminal cancer patients with different levels of age, gender, stated pain, request for painkillers, and signs of depression; 103 of them also indicated the acceptability of making frequent home visits in the same 48 scenarios. The responses were analyzed using analysis of variance and cluster analysis. For prescribing opiates, four clusters of physicians were found: 13 prescribed primarily in response to stated pain; 43 to request for painkillers; 43 to the combination of pain, request, and depression; and 16 in virtually all cases. Using the same clusters to analyze visiting gave results that were very consistent with those for prescribing. We conclude that French general practitioners have differing and consistent styles in prescribing painkillers and making home visits to dying cancer patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19797340     DOI: 10.1177/0269216309107012

Source DB:  PubMed          Journal:  Palliat Med        ISSN: 0269-2163            Impact factor:   4.762


  2 in total

1.  Mapping French people and health professionals' positions regarding the circumstances of morphine use to relieve cancer pain.

Authors:  Julie Mazoyer; Maria Teresa Muñoz Sastre; Paul Clay Sorum; Etienne Mullet
Journal:  Support Care Cancer       Date:  2017-03-31       Impact factor: 3.603

2.  The Issue of Burnout and Work Satisfaction in Younger GPs-A Cluster Analysis Utilizing the HaMEdSi Study.

Authors:  Oliver Hirsch; Charles Christian Adarkwah
Journal:  Int J Environ Res Public Health       Date:  2018-10-08       Impact factor: 3.390

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.